117 related articles for article (PubMed ID: 24074786)
1. From genome to bedside: are we lost in translation?
Hayes DF
Breast; 2013 Aug; 22 Suppl 2():S22-6. PubMed ID: 24074786
[TBL] [Abstract][Full Text] [Related]
2. Individualization of treatment strategies.
Fernández Ortega A; Jolis López L; Viñas Villaró G; Villanueva Vázquez R; García Arias A; González Farré X; González Jiménez S; Saura Manich C; Cortés Castán J
Adv Ther; 2011 Sep; 28 Suppl 6():19-38. PubMed ID: 21922393
[TBL] [Abstract][Full Text] [Related]
3. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy.
Huang EH; Tucker SL; Strom EA; McNeese MD; Kuerer HM; Buzdar AU; Valero V; Perkins GH; Schechter NR; Hunt KK; Sahin AA; Hortobagyi GN; Buchholz TA
J Clin Oncol; 2004 Dec; 22(23):4691-9. PubMed ID: 15570071
[TBL] [Abstract][Full Text] [Related]
4. Disease related indicators for a proper choice of adjuvant treatments.
Hayes DF
Breast; 2011 Oct; 20 Suppl 3():S162-4. PubMed ID: 22015287
[TBL] [Abstract][Full Text] [Related]
5. Biomarkers in early breast cancer and beyond: who needs all those tests?
Storz-Pfennig P; Wolf K
Lancet Oncol; 2014 Aug; 15(9):919-20. PubMed ID: 25079097
[No Abstract] [Full Text] [Related]
6. Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer.
Muñoz M; Estévez LG; Alvarez I; Fernández Y; Margelí M; Tusquets I; Seguí MA; Lluch A
Cancer Treat Rev; 2008 Dec; 34(8):701-9. PubMed ID: 18922644
[TBL] [Abstract][Full Text] [Related]
7. Personalized adjuvant therapies: lessons from the past: the opening address by the St. Gallen 2013 award recipient.
Goldhirsch A
Breast; 2013 Aug; 22 Suppl 2():S3-7. PubMed ID: 24074788
[TBL] [Abstract][Full Text] [Related]
8. Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination.
Yu H; Levesque MA; Clark GM; Diamandis EP
Br J Cancer; 1999 Oct; 81(3):490-5. PubMed ID: 10507775
[TBL] [Abstract][Full Text] [Related]
9. Personalized treatment of early-stage breast cancer: present concepts and future directions.
Harbeck N; Salem M; Nitz U; Gluz O; Liedtke C
Cancer Treat Rev; 2010 Dec; 36(8):584-94. PubMed ID: 20554119
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant endocrine therapy for breast cancer: don't ditch the switch!
Puhalla S; Jankowitz RC; Davidson NE
J Natl Cancer Inst; 2011 Sep; 103(17):1280-2. PubMed ID: 21859987
[No Abstract] [Full Text] [Related]
11. The continued evidence from overviews: what is the clinical utility?
Turner N; Biganzoli L; Malorni L; Migliaccio I; Moretti E; Pestrin M; Sanna G; Siclari O; Di Leo A
Breast; 2013 Aug; 22 Suppl 2():S8-11. PubMed ID: 24074798
[TBL] [Abstract][Full Text] [Related]
12. Influence of genomics on adjuvant treatments for pre-invasive and invasive breast cancer.
Abu-Khalf M; Pusztai L
Breast; 2013 Aug; 22 Suppl 2():S83-7. PubMed ID: 24074799
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA expression and its implications for the diagnosis and therapeutic strategies of breast cancer.
Shi M; Guo N
Cancer Treat Rev; 2009 Jun; 35(4):328-34. PubMed ID: 19171434
[TBL] [Abstract][Full Text] [Related]
14. Current comprehensive assessment and management of women at increased risk for breast cancer.
Hollingsworth AB; Singletary SE; Morrow M; Francescatti DS; O'Shaughnessy JA; Hartman AR; Haddad B; Schnabel FR; Vogel VG
Am J Surg; 2004 Mar; 187(3):349-62. PubMed ID: 15006563
[TBL] [Abstract][Full Text] [Related]
15. Molecular markers in the endometrium at baseline of postmenopausal patients with early breast cancer in the ATAC (Arimidex, tamoxifen, alone, or in combination) trial.
Duffy SR; Taylor L
Am J Obstet Gynecol; 2004 Dec; 191(6):1921-7. PubMed ID: 15592273
[TBL] [Abstract][Full Text] [Related]
16. Innovative biomarker development for personalized medicine in breast cancer care.
Zografos GC; Roukos DH
Biomark Med; 2011 Feb; 5(1):73-8. PubMed ID: 21319967
[No Abstract] [Full Text] [Related]
17. Multigene classifiers, prognostic factors, and predictors of breast cancer clinical outcome.
Ross JS
Adv Anat Pathol; 2009 Jul; 16(4):204-15. PubMed ID: 19546609
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.
Esteva FJ; Sahin AA; Smith TL; Yang Y; Pusztai L; Nahta R; Buchholz TA; Buzdar AU; Hortobagyi GN; Bacus SS
Cancer; 2004 Feb; 100(3):499-506. PubMed ID: 14745865
[TBL] [Abstract][Full Text] [Related]
19. [Molecular factors determine primary and secondary therapy of breast carcinoma].
Eppenberger U; Kueng W; Eppenberger-Castori S; von Landenberg EM; Müller H
Ther Umsch; 1997 Aug; 54(8):451-6. PubMed ID: 9381415
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of high-dose chemotherapy and autologous stem cell transplant in isolated locally recurrent breast cancer: a multicenter evaluation.
Vij R; DiPersio J; Brown R; Trinkaus K; Abboud C; Meehan KR; Frenette G; Freytes C; Goodnough LT; Khoury H; Ponnuri J; Adkins D
Bone Marrow Transplant; 2000 Nov; 26(9):947-53. PubMed ID: 11100273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
